Navigation Links
HearAtLast Continues Rapid Expansion, Opening Two New Retail Locations in Richmond Hill and Markham Wal-Mart Stores Number 3195 and 3053
Date:10/30/2007

TORONTO, Oct. 30 /PRNewswire-FirstCall/ -- HearAtLast Holdings, Inc. (Pink Sheets: HRAL) announced that it has received additional licenses from Wal-Mart Canada, a wholly owned subsidiary of Wal-Mart International, Inc. (NYSE: WMT), to open their ninth and tenth hearing-aid clinics in two Toronto area Wal-Mart Stores. Wal-Mart Store #3195 located at 1070 Major Mackenzie Drive in Richmond Hill and Wal-Mart Store #3053 located at 5000 Highway #7 Unit Y006A in Markham will both officially open today. This expansion is a direct result of the Company exercising its option under a master licensing agreement with Wal-Mart International which allows HearAtLast to open hearing aid clinics within numerous Wal-Mart locations throughout Canada.

"We are pleased to continue our expansion in the Greater Toronto area in these two prime locations. Richmond Hill is a stable, well-established community and one of the wealthiest suburbs in Ontario. Their consumer demographic is well suited for our business model. The Markham location is also quite attractive as it is the high tech capital of Canada and the seventh largest municipality in Ontario," stated Robert J. Oswald, President of HearAtLast. "This dual opening further proves that we are streamlining our expansion capabilities as we grow the business," Oswald added.

The addition of the Richmond Hill and Markham stores brings the current count of HearAtLast clinics co-located in Wal-Mart Stores to 10 locations in Canada, five of which are located in the Greater Toronto Ontario area.

For more information please visit http://www.hearatlast.com.

About HearAtLast

HearAtLast Holdings, Inc. is a Nevada corpor
'/>"/>

SOURCE HearAtLast Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. OxyContin Abuse Continues To Rise
2. Alzheimer’s Continues to Ris
3. Uttar Pradesh Encephalitis toll continues to rise - Over 600 dead
4. Human Brain Continues To Evolve And Grow
5. War Against Cancer Continues
6. Botswana Continues Its Fight Against AIDS
7. US Continues Its War On Diabetes
8. Polio Continues To Haunt India
9. Reservation boycott by Medical student fraternity continues in Bangalore
10. Patients Left Helpless As Mumbai Doctors Strike Continues
11. Health Services Came To A Halt As Mumbai Doctors Strike Continues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)... , Four scientific studie...specially after 9 p.m., can increase the likelihoo...at cell phone radiation, as well as those from oth...nes; all cause a build-up of damaging free radical...sly suppress the synthesis of the sleep-controllin...
(Date:1/7/2009)... , SOUTH BEND, Ind., Jan. 8 ...has acquired PatientFlow Technology (PatientFlow),...ols and services for hospitals.,The Boston-based ...ns by,offering strategic solutions for patient fl...ng wait times, bumped or delayed surgeries, and la...
(Date:1/7/2009)... , WEST PALM BEACH, Fla., Jan. 7 Non-profits Medi...ation.com ) and Monterrey Health Care City ( www...together to create the 1st Latin America Medical T...pril 27-29th, 2009 in Monterrey, Mexico at the Int...ne of the top destinations of medical tourism in L...
(Date:1/7/2009)... , BEDFORD, Mass., Jan. 7 Insulet Corporation (Na...y with its OmniPod(R) Insulin Management System, t... 27th Annual J.P. Morgan Healthcare Conference. Ma...e Company at 7:30 a.m. PST on January 14, 2009 at ...During the conference presentation, material infor...
Breaking Medicine News(10 mins):Health News:Welsh Laboratory Discovers Natural Antidote for Sleep Disturbance Caused by Cell Phones; Don't Disturb Me! Asphalia for Natural Sleep 2Health News:Welsh Laboratory Discovers Natural Antidote for Sleep Disturbance Caused by Cell Phones; Don't Disturb Me! Asphalia for Natural Sleep 3Health News:Press Ganey Acquires PatientFlow Technology 2Health News:The Non-Profits Medical Tourism Association (MTA), Monterrey Health Care City (MHCC) Have Partnered Together to Create the 1st Latin America Medical Tourism and Health Tourism Congress Which Occurs April 27-29th, 2009 in Monterrey, Mexico at the Intercont 2Health News:The Non-Profits Medical Tourism Association (MTA), Monterrey Health Care City (MHCC) Have Partnered Together to Create the 1st Latin America Medical Tourism and Health Tourism Congress Which Occurs April 27-29th, 2009 in Monterrey, Mexico at the Intercont 3Health News:The Non-Profits Medical Tourism Association (MTA), Monterrey Health Care City (MHCC) Have Partnered Together to Create the 1st Latin America Medical Tourism and Health Tourism Congress Which Occurs April 27-29th, 2009 in Monterrey, Mexico at the Intercont 4
...m, a shelter home here, combines spirituality with...urial process . Authorities at the Sewadham Ashra... instead of consigning the mortal remains to flame...ition. The burial process is eco-friendly as it p...
...om MIT's Picower Institute for Learning and Memory... the formation of fears stemming from traumatic ev...reat the millions of adults who suffer each year f...ears - including hundreds of soldiers returning fr...
...s alarmingly found that more than 90 per cent of w...g the wrong doses of fertility drugs meant to stim... not only means that the drugs may not work proper...may be exposing women to a greater risk of side ef...
...Chronic Obstructive Pulmonary Disease (COPD) are i...ds to control exacerbations of the disease , but a...increase the chances that these patients will be h...cohort of patients with COPD, we found that curren...
Other Medicine News:Health News:First Drug for Post-traumatic Stress Disorder 2Health News:Patients Taking Inhaled Steroids may Develop Pneumonia 2
(Date:1/7/2009)..., Late Preterm Infants Drive the Increase , , ... -- New government statistics confirm that the dec...rate continues, putting more infants than ever at ...o the March of Dimes. , , Nearly 543,000 babies...onal Center for Health Statistics, which today rel...
(Date:1/6/2009)..., Program Expands on Successful Results from prio...n. 7 Vital Therapies, Inc. (VTI), ...e, today announced patient enrollment has begun fo...clinical trial that will study the Extracorporeal ...ents with Acute Liver Failure (ALF) under three pr...
(Date:1/6/2009)..., CAMBRIDGE, Mass., Jan. 6 Cequen... novel products to deliver RNAi-based treatments t...the company has recently completed a successful to...administered tk RNAi therapeutic targeting the pr...lial adenomatous polyposis). FAP is an inherited g...
(Date:1/5/2009)..., SAN JOSE, Calif., Jan. 5 Wo...re progesterone medication to help support early,...me forms of this medication,can be painful for pa...hich,can be administered by subcutaneous injectio...s with better patient tolerance. , With pat...
Breaking Medicine Technology:Preterm Births Rise 36 Percent Since Early 1980s 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 2Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 3Fertility Physicians of Northern California Researchers Test New Forms of Progesterone Medication for Luteal Support During IVF 2Experts Agree There is No Scientific Evidence of Health Risks in New Jersey Synthetic Turf Fields 17347 1Experts Agree There is No Scientific Evidence of Health Risks in New Jersey Synthetic Turf Fields 17347 2Experts Agree There is No Scientific Evidence of Health Risks in New Jersey Synthetic Turf Fields 17347 3VNUS Medical Technologies Reports First Quarter 2008 Results 3A 21 25 growth in Net Revenues and 51 25 Growth in Unit Sales 4744 1VNUS Medical Technologies Reports First Quarter 2008 Results 3A 21 25 growth in Net Revenues and 51 25 Growth in Unit Sales 4744 2VNUS Medical Technologies Reports First Quarter 2008 Results 3A 21 25 growth in Net Revenues and 51 25 Growth in Unit Sales 4744 3VNUS Medical Technologies Reports First Quarter 2008 Results 3A 21 25 growth in Net Revenues and 51 25 Growth in Unit Sales 4744 4VNUS Medical Technologies Reports First Quarter 2008 Results 3A 21 25 growth in Net Revenues and 51 25 Growth in Unit Sales 4744 5VNUS Medical Technologies Reports First Quarter 2008 Results 3A 21 25 growth in Net Revenues and 51 25 Growth in Unit Sales 4744 6VNUS Medical Technologies Reports First Quarter 2008 Results 3A 21 25 growth in Net Revenues and 51 25 Growth in Unit Sales 4744 7Off Hours Heart Patients Less Likely to Get Angioplasty 17343 1Off Hours Heart Patients Less Likely to Get Angioplasty 17343 2Improving quality of life for brain tumor patients 17340 1Improving quality of life for brain tumor patients 17340 2Improving quality of life for brain tumor patients 17340 3
...HLIEREN (Zurich), Switzerland, March 13, 2007 -,Cy...itive results,from a phase IIa study with CYT003-Q...he treatment of allergic diseases. The study,inclu...lergic,rhinitis due to grass pollen allergy (hay f...ting the safety, tolerability and,exploratory effi...
...DNEY, Australia, March 14, 2007 /Xinhua-PRNewswire...day announced the results,from its Phase II trial ...lmonary Disease (COPD), a respiratory disease,affe...l was conducted in 79 diagnosed COPD patients at 1...he trial was to,determine if subjects that were po...
Other Medicine Technology:Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 2Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 3Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 4Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 5Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 6Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 7Pharmaxis Reports Phase II Results for Aridol in COPD 2Pharmaxis Reports Phase II Results for Aridol in COPD 3Pharmaxis Reports Phase II Results for Aridol in COPD 4
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
Medicine Products: